Illinois is currently home to 2668 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
NCT04464226
Recruiting
The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Jesse Brown VA Medical Center - Cardiology, Chicago, Illinois
Conditions: Cancer
Register for Updates
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
NCT04241835
Recruiting
This main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the study drug tazemetostat. The pharmacokinetics of the study drug in participants with advanced solid tumors and moderate or severe hepatic (liver) impairment will be compared with participants with advanced malignancies and normal hepatic function. An advanced malignancy is a cancer that has recurred (come back) after prior treatment or hasn't controlled with treatment. The trial will also study th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois
Conditions: Hepatic Impairment, Advanced Malignant Solid Tumor
Register for Updates
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493
Recruiting
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to esta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Register for Updates
A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
NCT04123795
Recruiting
The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/31/2025
Locations: Ps0007 50168, Chicago, Illinois
Conditions: Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
Register for Updates
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
NCT04097145
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
Register for Updates
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022
Recruiting
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Site US10002, Chicago, Illinois
Conditions: Prostate Cancer
Register for Updates
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
NCT06898450
Recruiting
The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main questions it aims to answer are: Is NDI-219216 safe and what kinds of side effects might it cause? What kind of effects does NDI-219216 have on the body? Does NDI-219216 have any impact on tumor size? Participants will: Take NDI-219216 every day by mouth. Visit the clinic 6 times during Cycle 1, 2... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/30/2025
Locations: University of Chicago Medicine, Chicago, Illinois
Conditions: Advanced Solid Tumors Cancer, MSI-H Cancer
Register for Updates
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
NCT06803342
Recruiting
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/30/2025
Locations: Synexus Clinical Research US, Inc., Chicago, Illinois
Conditions: Ebola Sudan Virus Disease
Register for Updates
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
NCT06747858
Recruiting
ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: The Cystic Fibrosis Institute, Northfield, Illinois
Conditions: Cystic Fibrosis, CFTR Gene Mutation
Register for Updates
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496
Recruiting
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Clinic of Robert Hozman, Skokie, Illinois
Conditions: Psoriatic Arthritis
Register for Updates
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483
Recruiting
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: GSCP/CIS, Orland Park, Illinois
Conditions: Psoriatic Arthritis
Register for Updates
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
NCT06654752
Recruiting
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
Gender:
ALL
Ages:
Between 3 years and 18 years
Trial Updated:
07/30/2025
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago & Northwestern University, Chicago, Illinois
Conditions: Cystic Fibrosis
Register for Updates